These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9432029)

  • 1. Decreased half-life time of plasma von Willebrand factor collagen binding activity in essential thrombocythaemia: normalization after cytoreduction of the increased platelet count.
    van Genderen PJ; Prins FJ; Lucas IS; van de Moesdijk D; van Vliet HH; van Strik R; Michiels JJ
    Br J Haematol; 1997 Dec; 99(4):832-6. PubMed ID: 9432029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
    Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
    Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count.
    van Genderen PJ; Budde U; Michiels JJ; van Strik R; van Vliet HH
    Br J Haematol; 1996 Jun; 93(4):962-5. PubMed ID: 8703834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Qualitative and quantitative modifications of von Willebrand factor in patients with essential thrombocythemia and controlled platelet count.
    Lancellotti S; Dragani A; Ranalli P; Petrucci G; Basso M; Tartaglione R; Rocca B; De Cristofaro R
    J Thromb Haemost; 2015 Jul; 13(7):1226-37. PubMed ID: 25876231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abnormal collagen binding activity of 2A von Willebrand factor: evidence that the defect depends only on the lack of large multimers.
    Casonato A; Pontara E; Bertomoro A; Zucchetto S; Zerbinati P; Girolami A
    J Lab Clin Med; 1997 Feb; 129(2):251-9. PubMed ID: 9016863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma.
    Budde U; Scharf RE; Franke P; Hartmann-Budde K; Dent J; Ruggeri ZM
    Blood; 1993 Sep; 82(6):1749-57. PubMed ID: 8400231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Excessive prolongation of the bleeding time by aspirin in essential thrombocythemia is related to a decrease of large von Willebrand factor multimers in plasma.
    van Genderen PJ; van Vliet HH; Prins FJ; van de Moesdijk D; van Strik R; Zijlstra FJ; Budde U; Michiels JJ
    Ann Hematol; 1997; 75(5-6):215-20. PubMed ID: 9433378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased cleavage of von Willebrand factor by ADAMTS13 may contribute strongly to acquired von Willebrand syndrome development in patients with essential thrombocythemia.
    Kubo M; Sakai K; Hayakawa M; Kashiwagi H; Yagi H; Seki Y; Hasegawa A; Tanaka H; Amano I; Tomiyama Y; Matsumoto M
    J Thromb Haemost; 2022 Jul; 20(7):1589-1598. PubMed ID: 35352474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
    Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
    Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management.
    Michiels JJ; Budde U; van der Planken M; van Vliet HH; Schroyens W; Berneman Z
    Best Pract Res Clin Haematol; 2001 Jun; 14(2):401-36. PubMed ID: 11686107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High resolution multimer analysis and the PFA-100 platelet function analyser can detect von Willebrand disease type 2A without a pathological ratio of ristocetin cofactor activity and von Willebrand antigen level.
    Weiss DR; Strasser EF; Ringwald J; Zimmermann R; Eckstein R
    Clin Lab; 2012; 58(11-12):1203-9. PubMed ID: 23289190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease.
    Jilma B; Paulinska P; Jilma-Stohlawetz P; Gilbert JC; Hutabarat R; Knöbl P
    Thromb Haemost; 2010 Sep; 104(3):563-70. PubMed ID: 20589313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients with severe von Willebrand disease are insensitive to the releasing effect of DDAVP: evidence that the DDAVP-induced increase in plasma factor VIII is not secondary to the increase in plasma von Willebrand factor.
    Cattaneo M; Simoni L; Gringeri A; Mannucci PM
    Br J Haematol; 1994 Feb; 86(2):333-7. PubMed ID: 8199023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
    Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new variant of von Willebrand's disease (type I Padua): doublet-organized plasma von Willebrand factor oligomers in the presence of all size multimers.
    Casonato A; Pontara E; Dannhäuser D; Bertomoro A; Sartori MT; Girolami A
    Haematologia (Budap); 1994; 26(2):97-109. PubMed ID: 7890268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. von Willebrand factor-collagen binding activity is increased in newborns and infants.
    Thomas KB; Sutor AH; Altinkaya N; Grohmann A; Zehenter A; Leititis JU
    Acta Paediatr; 1995 Jun; 84(6):697-9. PubMed ID: 7670260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired von Willebrand's disease in association with essential thrombocythemia: regression following treatment.
    Murakawa M; Okamura T; Tsutsumi K; Tanoguchi S; Kamura T; Shibuya T; Harada M; Niho Y
    Acta Haematol; 1992; 87(1-2):83-7. PubMed ID: 1585777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased amounts of von Willebrand factor are bound to microparticles after infusion of desmopressin.
    Trummer A; Haarmeijer B; Werwitzke S; Wermes C; Ganser A; Budde U; Tiede A
    Haemophilia; 2013 Mar; 19(2):236-41. PubMed ID: 23051555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.